[HTML][HTML] A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
M Lübbert, BH Rüter, R Claus, C Schmoor… - …, 2012 - ncbi.nlm.nih.gov
haematologica, 2012•ncbi.nlm.nih.gov
Background The treatment of acute myeloid leukemia of older, medically non-fit patients still
poses a highly unmet clinical need, and only few large, prospective studies have been
performed in this setting. Given the established activity of hypomethylating agents such as 5-
aza-2'-deoxycytidine (decitabine) in myelodysplastic syndromes and acute myeloid
leukemia with 20–30% bone marrow blasts, we investigated whether this drug is also active
in patients with more than 30% blasts.
poses a highly unmet clinical need, and only few large, prospective studies have been
performed in this setting. Given the established activity of hypomethylating agents such as 5-
aza-2'-deoxycytidine (decitabine) in myelodysplastic syndromes and acute myeloid
leukemia with 20–30% bone marrow blasts, we investigated whether this drug is also active
in patients with more than 30% blasts.
Abstract
Background
The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this setting. Given the established activity of hypomethylating agents such as 5-aza-2'-deoxycytidine (decitabine) in myelodysplastic syndromes and acute myeloid leukemia with 20–30% bone marrow blasts, we investigated whether this drug is also active in patients with more than 30% blasts.
ncbi.nlm.nih.gov